Select Language : myClaris
Claris Lifesciences Limited - India

Claris Lifesciences Limited


Claris Lifesciences to mkt products in Finland

The Economic Times, Ahmedabad

PHARMAEUT1CAL company Claris Life-sciences has entered into a strategic alliance with the1.4 billion Danish Kroner firm Copyfarm for marketing its products in Finland. Claris received the good manufacturing practices (GMP} approval from Finland regulatory authority, a senior company executive told ET today.

The company is expecting a market share of close to 3.56 million euros from its products in the 1,571 million euro Finland market. With this approval, Claris is looking at marketing its bestseller anesthetic, Propofol intravaneous injection, along with high-end anti-infectives such as ciprofloxacin and metronidazole in the Finnish market.

Claris said that it also gearing up to introduce a couple of more specialty critical-care products in the near future.

Claris Lifesciences has expertise in manufacturing and marketing injectables products. The company's range of products and delivery systems extends across enteral and parenteral nutrition, anaesthesia, blood products and plasma volume expanders, anti infectives, dialysis and transplant, cardiac care,


infusion therapy as well as medical disposables and equipments.

The Sushil Handa-promoted company is also planning to double its turnover to Rs 500 crore by the end of this financial year from Rs 225 crore at present. Exports account for close to 50 % of the company's turnover at present.

Claris had recently entered into a supply agreement with two international pharma players — PlasmaSelect of Germany and Australian pharma company Mayne Pharmay — for marketing lipids, fat emulsion and profol.

Profol is registered in more than 30 countries. Claris has a presence in more than 60 countries and plans to further extend it to 75 countries. At present, around five companies are believed to be present in this segment.

The European market will be the thrust area for the company for lipids, fat emulsion and profol. Industry sources say that the US, Latin American and Gulf markets are strong areas for this product segment. After establishing its presence in the markets where it has strategic tie-ups, Claris is expected to focus on other countries.

Claris Lifesciences Ltd. All Rights Reserved.  :: Terms of Use  ::Privacy Policy   :: Sitemap